In the canonical pathway, receptors that detect cytokines or microbial products signal to the IκB kinase complex. This complex phosphorylates IκB, marking the inhibitor for ubiquitination and proteasomal degradation. Removing IκB permits NF-κB to enter the nucleus, where it regulates expression of genes involved in the cellular response.
IκB restrains NF-κB before stimulation by preventing its access to the nucleus. Phosphorylation followed by ubiquitination and proteasomal degradation removes that restraint, converting an upstream signal into nuclear gene regulation. Because this step controls NF-κB release, it provides an important mechanistic point for interpreting pathway activity and therapeutic modulation.
Cytokines, microbial products, inflammation, and cellular stress can all provide signals associated with NF-κB activation. The pathway therefore connects environmental or tissue-level challenges with changes in gene expression. In medicine, identifying the initiating stimulus helps place NF-κB activity within broader processes such as immune defense, infection, inflammation, or tissue injury.
Researchers examine this pathway to connect inflammatory signals with altered gene expression and disease biology. In inflammatory and autoimmune disorders, the findings can help explain how immune-related responses become associated with persistent or harmful tissue effects. This disease-focused analysis supports evaluation of NF-κB activity as part of understanding mechanisms and disease activity.
Because the pathway contains identifiable signaling steps, including IκB kinase activity, IκB processing, and NF-κB nuclear entry, it offers points for therapeutic investigation. Medicine can use pathway studies to explore treatments that modulate rather than simply describe inflammatory signaling. Such work is relevant to inflammatory disease, autoimmune disorders, cancer progression, and tissue injury.
NF-κB activation links responses to infection, inflammation, and stress with changes in gene expression, so its significance extends beyond short-term immune defense. Medical research examines how this signaling relates to cancer progression and tissue injury, while also considering pathway activity as a possible biomarker of disease activity and treatment response.